Phase I/II and Pharmacokinetic Study of Intravenous Vinflunine in Combination With Cisplatin for the Treatment of Chemonaive Patients With Advanced Non-Small-Cell Lung Cancer

被引:19
|
作者
Souquet, Pierre-Jean [2 ]
Krzakowski, Maciej [3 ]
Ramlau, Rodrig [4 ]
Sun, Xu-Shan [5 ]
Lopez-Vivanco, Guillermo [6 ]
Puozzo, Christian [1 ]
Pouget, Jean Christophe [1 ]
Pinel, Marie Claire [1 ]
Rosell, Rafael [7 ]
机构
[1] Inst Rech Pierre Fabre, F-92100 Boulogne, France
[2] Ctr Hosp Lyon Sud, F-69310 Pierre Benite, France
[3] Ctr Onkol, Warsaw, Poland
[4] Wielkopolskie Ctr Chorob, Poznan, Poland
[5] Hop Andre Bouloche, Montbeliard, France
[6] Hosp Cruces, Baracaldo, Spain
[7] Hosp Badalona Germans Trias & Pujol, Barcelona, Spain
关键词
Drug-drug interaction; Free platinum; Maximum tolerated dose; Neutropenia; EVERY; 3; WEEKS; CLINICAL-TRIALS; III TRIAL; PLUS GEMCITABINE; VINCA ALKALOIDS; SOLID TUMORS; IN-VITRO; CHEMOTHERAPY; VINORELBINE; DRUGS;
D O I
10.3816/CLC.2010.n.014
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: A multicenter phase I/II trial of vinflunine administered in combination with cisplatin at 80 mg/m(2) was conducted in order to determine the dose-limiting toxicities, the maximum tolerated dose, and the recommended dose of the combination. An eventual mutual pharmacokinetic drug-drug interaction when vinflunine and cisplatin were coadministered was also evaluated. The study was also intended to define the response rate of vinflunine in combination with cisplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC) at the recommended dose. Patients and Methods: Patients were required to have a histologically confirmed diagnosis of NSCLC not amenable to curable treatment or stage IV disease. Patients may have had previous surgery for NSCLC but were to be chemonaive and have at least 1 bidimensional measurable lesion outside an irradiated area. Results: The recommended dose was established at cisplatin 80 mg/m(2) combined with vinflunine 320 mg/m(2). No unexpected adverse events were seen. Pharmacokinetic analysis supported the absence of mutual pharmacokinetic interaction when vinflunine and cisplatin are given in combination. Treatment of 53 patients at this recommended dose demonstrated a tumor response rate of 32.1% in the intent-to-treat population; disease control was achieved in 79.2% of the patients. The median progression-free survival and overall survival were estimated at 5 months and 10.4 months, respectively, and the 1-year survival rate was 43.4%. Conclusion: These results place the vinflunine/cisplatin combination among the most active doublets in this treatment setting and warrant further development in phase III trials of first-line treatment of patients with advanced metastatic NSCLC.
引用
收藏
页码:105 / 113
页数:9
相关论文
共 50 条
  • [31] A phase II study of docetaxel and infusional cisplatin in advanced non-small-cell lung cancer
    Mori, K
    Kamiyama, Y
    Kondo, T
    Kano, Y
    Kodama, T
    CHEMOTHERAPY, 2005, 51 (2-3) : 120 - 125
  • [32] Phase I study of a carboplatin-cisplatin-etoposide combination chemotherapy in advanced non-small-cell lung cancer
    Nakano, H
    Tsuchiya, S
    Takei, Y
    Minato, K
    Watanabe, S
    Makimoto, T
    Naruse, I
    Nomoto, T
    Ishihara, S
    Takise, A
    Ezawa, K
    Fueki, N
    Hoshino, H
    Saito, R
    Mori, M
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1996, 19 (03): : 245 - 248
  • [33] A phase I study of irinotecan and infusional cisplatin for advanced non-small-cell lung cancer
    K. Mori
    Tsukasa Ohnishi
    Kohki Yokoyama
    Keigo Tominaga
    Cancer Chemotherapy and Pharmacology, 1997, 39 : 327 - 332
  • [34] A phase I study of irinotecan and infusional cisplatin for advanced non-small-cell lung cancer
    Mori, K
    Ohnishi, T
    Yokoyama, K
    Tominaga, K
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1997, 39 (04) : 327 - 332
  • [35] A phase II study of paclitaxel plus cisplatin for advanced non-small-cell lung cancer in Japanese patients
    Hiroshi Sakai
    Shuichi Yoneda
    Tomohide Tamura
    Yutaka Nishiwaki
    Akira Yokoyama
    Koshiro Watanabe
    Nagahiro Saijo
    Cancer Chemotherapy and Pharmacology, 2001, 48 : 499 - 503
  • [36] Phase II study of weekly docetaxel combined with cisplatin in patients with advanced non-small-cell lung cancer
    Tsunoda, T
    Koizumi, T
    Hayasaka, M
    Hirai, K
    Koyama, S
    Takabayashi, Y
    Fujimoto, K
    Kubo, K
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2004, 54 (02) : 173 - 177
  • [37] Phase II study of weekly docetaxel combined with cisplatin in patients with advanced non-small-cell lung cancer
    Toshiyuki Tsunoda
    Tomonobu Koizumi
    Muneharu Hayasaka
    Kazuya Hirai
    Shigeru Koyama
    Yasuki Takabayashi
    Keisaku Fujimoto
    Keishi Kubo
    Cancer Chemotherapy and Pharmacology, 2004, 54 : 173 - 177
  • [38] A phase II study of paclitaxel plus cisplatin for advanced non-small-cell lung cancer in Japanese patients
    Sakai, H
    Yoneda, S
    Tamura, T
    Nishiwaki, Y
    Yokoyama, A
    Watanabe, K
    Saijo, N
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2001, 48 (06) : 499 - 503
  • [39] Phase I study of amrubicin and cisplatin in previously untreated patients with advanced non-small-cell lung cancer
    Yoshimura, N.
    Kudoh, S.
    Kimura, T.
    Mitsuoka, S.
    Yana, T.
    Hirata, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [40] Phase I and Pharmacokinetic Study of Pemetrexed plus Cisplatin in Chemonaive Patients with Locally Advanced or Metastatic Malignant Pleural Mesothelioma or Non-Small Cell Lung Cancer
    Dickgreber, Nicolas J.
    Fink, Thomas H.
    Latz, Jane E.
    Hossain, Anwar M.
    Musib, Luna C.
    Thomas, Michael
    CLINICAL CANCER RESEARCH, 2009, 15 (01) : 382 - 389